BD1 secures Japanese patent towards cancer treatments

Published at Feb 2, 2018, in Biotech

Biotech play BARD1 Life Sciences Limited (ASX:BD1) today announced that it has received a Japanese patent for its BARD1 isoforms.

On 12 January 2018, the Japan Patent Office issued the Japanese Patent number P6271636 titled “BARD1 isoforms in lung and colorectal cancer and use thereof”.

This patent family protects the sequence of various BARD1 isoforms specific to lung and colorectal cancer, a method for detecting the presence of the specific BARD1 isoforms, and a method for treating and/or preventing lung cancer and colorectal cancer.

BD1 is a small cap biotechnology company developing non-invasive cancer diagnostics.

Earlier in the month, it announced it had received positive results from its OC-400 Study that showed BARD1-Ovarian achieved high accuracy for detection of ovarian cancer.

BARD1 has now successfully completed the retrospective, case-control, OC-400 Study which was intended to evaluate the accuracy of the multi-analyte BARD1-Ovarian test to detect ovarian cancer in 400 female bio-banked samples of ovarian cancer and aged-matched healthy controls.

While there’s plenty of good news coming from BD1, it should be noted it an early stage stock and investors should seek professional financial advice if considering it for their portfolio.

Patent specifics

The Japan Patent Office issued the P6271636 patent for BARD1 isoforms in the treatment of lung and colorectal cancer — providing further protection over the parent case P5938406 for modulators, such as siRNA molecules, of specific BARD1 isoforms for use in the treatment or prevention of lung or colorectal cancer.

That patent was filed in the name of Université De Genève (UNIGE) and Hôpitaux Universitaires de Genève (HUG) on 17 August 2011, and is due to expire on 17 August 2031.

BARD1 LSL (via its fully owned subsidiary BARD1AG SA) has licensed the commercial rights to exploit this technology from UNIGE and HUG.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn